SpringWorks Therapeutics Announces FDA Approval of OGSIVEO (

28.11.2023 - – Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life ...

Related Keywords

New York , United States , Memorial Sloan Kettering Cancer Center , Springworks Careconnections , Samantha Hilson Sandler , Saqib Islam , Jeanne Whiting , Linkedin , Founder Of The Desmoid Tumor Research Foundation , Exchange Commission , Us Department Of Commerce , Twitter , Desmoid Tumor Working Group , Nasdaq , Springworks Therapeutics Inc , European Medicines Agency , Drug Administration , Works Therapeutics , Chief Executive Officer , Memorial Sloan , Kettering Cancer Center , New York City , New England Journal , Important Safety Information , Executive Director Emeritus , Desmoid Tumor Research , Authorisation Application , Melanoma Skin Cancers , Embryo Fetal Toxicity , Acid Reducing Agents , Prescribing Information , Springworks Therapeutics , Private Securities Litigation Reform Act , Springwork Quarterly Report , Dei Tos , Soft Tissue Tumours , Tumor Working , Gamma Secretase Inhibitor , Report Series , Rare Diseases , Springworks Therapeutics Chart , Pringworks Therapeutics Kurs , Pringworks Therapeutics Aktie ,